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Transfusion dependent thalassaemia is a significant problem in Sri Lanka. In a study published in 2000, it was estimated that there were approximately 2000 transfusion dependent beta thalassaemia and HbE patients in Sri Lanka and the expenditure on them accounted for approximately 5% of the recurrent health budget of the country [1] . This number has by and large remained static over the past decade. An Italian group reported in 2006, that the mean cost of treatment for thalassaemia major was € 1242/patient/month with 55.5% of it attributed to iron chelation therapy and 33.2% attributed to blood transfusion [2] . Bone marrow transplant (BMT) is the only established cure for thalassaemia at present.
A 7-year old boy with severe thalassaemia was referred by the Lanka Thalassaemia Circle to the BMT Unit at the Central Hospital for a MSD BMT. He was confirmed to have beta thalassaemia by haemoglobin HPLC and had undergone over 70 blood transfusions since the age of 6 months. He was on iron chelation for the past six years. He had the same HLA type as his elder sister. HLA typing was independently performed and confirmed in two laboratories -Histogenetics, USA and DKMS (German Marrow Donor Programme), Germany.
The patient was categorised low risk by age and liver size [3] . He was admitted to the BMT Unit after insertion of a single lumen central venous line (CVL). Conditioning consisted of Rabbit Genzyme Thymoglobulin, Busulfan and Cyclophosphamide. GVHD prophylaxis consisted of cyclosporin A, a ''short'' methotrexate course and methylprednisolone. On D-0, his elder sister, who had been given G-CSF 5 u/kg sub-cutaneously for 3 days, underwent a bone marrow harvest under general anaesthesia. A total nucleated cell dose of 10x10 8 /kg was harvested and transfused to the patient via CVL without any complications. Platelet engraftment (the first day of 20x10 9 /l platelet count with no platelet transfusion in the preceding week) was on D+19 while neutrophil engraftment (the first of three consecutive days with an absolute neutrophil To the Editors:
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count >0.5x10 9 /l) was on D+21. In the interim period he developed a CVL related, culture positive, bacterial infection that responded to first line antibiotics. He had a stable mixed chimerism of between 75%-80% donor in peripheral blood from D+30 until D+90, when it was last checked. Chimerism testing was not performed thereafter, as his haemoglobin was persistently >100 g/l. His last blood transfusion was on D+12. He remained free of cytomegalovirus infection and had no evidence of graft versus host disease (GVHD) at D+100. Tailing off cyclosporin was started very slowly. He remains transfusion-independent 9 months post-transplant, doing well with no GVHD or other transplant related complications. His performance score is 100%.
BMT can cure over 85% of low-risk children with thalassemia having a fully compatible sibling and improve health-related quality of life in the great majority of them [4] . Furthermore, it is a curative option not only for thalassaemia and haemoglobinopathies but for many high-risk haematological malignancies, aplastic anaemia, and inherited immune deficiency syndromes. Therefore, starting a BMT programme has provided the opportunity of a cure for many patients who would otherwise have to travel overseas and contributed to cost savings for the country by making iron chelation which accounts for 55% of the cost of treatment of transfusion dependent thalassaemia redundant. The BMT was performed in close collaboration with an Italian organization (Cure 2Children Foundation) that has specific experience and tools for professional support to start BMT units in low and middle-income countries.
One of the main obstacles for BMT is the lack of HLA matched donors. However, with haplo-identical transplants becoming popular worldwide and the experience in finding the right combination of drugs used for conditioning and GVHD prophylaxis increasing, it is expected that all patients could potentially have BMT in the near future with acceptable survival. We read with interest the article by Wijayarathna et al. offering retrograde ureteric stenting (RUS) as the urinary drainage of first choice to all patients with recurrent malignancies in the pelvic cavity causing malignant ureteric obstruction (MUO) [1] . The authors knew that most of these patients had exhausted the primary modalities of treatment of their respective malignancies and regrettably, they still performed 'palliative' urinary diversion routinely. This paper fails to state the number of patients with bilateral ureteric obstruction, percentage of them with uraemia, and ureteric units successfully stented. In MUO, 'palliative' urinary diversion, percutaneous nephrostomy (PCN) or RUS, should be performed only if there is a definitive treatment plan available for the patient as the quality of life can be suboptimal and the patient's ability to return home for at least 2 months prior to death is often compromised by such unnecessary intervention.
Fifty three patients (64.6%) had demonstrable pelvic tumour recurrence but RUS was successful only in 15 patients (28.3% of this group). The authors fail to state what they offered to the majority (38 patients) that failed RUS. Were they considered for immediate PCN? The finding that in spite of successful RUS 13 of 15 patients (87%) were dead within 3 months of stenting corroborates my notion that routine RUS /PCN is not in the best interest of the patient. What was the plight of those patients with pelvic tumour recurrence that failed RUS? Early deaths, in 87% of patients with successful stent placement, should be construed as non-palliated, although RUS is offered as a palliative procedure. The question that begs an answer is what symptom palliation have you achieved using RUS? This paper fails to portray the cardinal symptoms affecting the patients with MUO that the authors set out to palliate, the severity of such symptoms and the onset, duration and the degree of symptom improvement after RUS. Palliation should be viewed as a three-dimensional concept, namely onset, duration and degree of symptom relief [2] . Prophylaxis before surgery (9 cases), certainly not ureteric obstruction, should be excluded. The authors do not define high/low serum creatinine.
Izumi et al. reported a series of gynaecological and gastrointestinal MUO patients [3] . Four prognostic factors: pre-diversion serum creatinine (over 1.2 mg/ dl), availability of cancer therapy, location of primary malignancy and presence of bilateral ureteric obstruction
